ImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losers
May 15, 2019 at 14:11 PM EDT
Shares of ImmunoGen Inc. led biotech’s losers on Wednesday, falling 38% in intraday trade after the company disclosed that the U.S. Food and Drug Administration had recommended it run a second Phase 3 trial of an ovarian cancer drug.
